380 related articles for article (PubMed ID: 33466394)
21. Recent advances in the diagnostic and therapeutic roles of microRNAs in colorectal cancer progression and metastasis.
Liang C; Yang JB; Lin XY; Xie BL; Xu YX; Lin S; Xu TW
Front Oncol; 2022; 12():911856. PubMed ID: 36313731
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and clinical monitoring strategies for immune checkpoint inhibitors and targeted cytokine immunotherapy for locally advanced and metastatic colorectal cancer.
Bess SN; Greening GJ; Muldoon TJ
Cytokine Growth Factor Rev; 2019 Oct; 49():1-9. PubMed ID: 31679887
[TBL] [Abstract][Full Text] [Related]
23. Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer.
Hurwitz H
Clin Colorectal Cancer; 2004 Oct; 4 Suppl 2():S62-8. PubMed ID: 15479481
[TBL] [Abstract][Full Text] [Related]
24. Intestinal microbiota and colorectal carcinoma: Implications for pathogenesis, diagnosis, and therapy.
Montalban-Arques A; Scharl M
EBioMedicine; 2019 Oct; 48():648-655. PubMed ID: 31631043
[TBL] [Abstract][Full Text] [Related]
25. Colorectal Cancer-Infiltrating Regulatory T Cells: Functional Heterogeneity, Metabolic Adaptation, and Therapeutic Targeting.
Aristin Revilla S; Kranenburg O; Coffer PJ
Front Immunol; 2022; 13():903564. PubMed ID: 35874729
[TBL] [Abstract][Full Text] [Related]
26. Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer.
Galizia G; Lieto E; De Vita F; Orditura M; Castellano P; Troiani T; Imperatore V; Ciardiello F
Oncogene; 2007 May; 26(25):3654-60. PubMed ID: 17530019
[TBL] [Abstract][Full Text] [Related]
27. Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer.
Luo HY; Xu RH
World J Gastroenterol; 2014 Apr; 20(14):3858-74. PubMed ID: 24744578
[TBL] [Abstract][Full Text] [Related]
28. Recruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges.
Al-Hujaily EM; Al-Sowayan BS; Alyousef Z; Uddin S; Alammari F
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430176
[TBL] [Abstract][Full Text] [Related]
29. PD-1/PD-L1-dependent immune response in colorectal cancer.
Payandeh Z; Khalili S; Somi MH; Mard-Soltani M; Baghbanzadeh A; Hajiasgharzadeh K; Samadi N; Baradaran B
J Cell Physiol; 2020 Jul; 235(7-8):5461-5475. PubMed ID: 31960962
[TBL] [Abstract][Full Text] [Related]
30. Circulating microRNAs as Promising Biomarkers in Colorectal Cancer.
Rapado-González Ó; Álvarez-Castro A; López-López R; Iglesias-Canle J; Suárez-Cunqueiro MM; Muinelo-Romay L
Cancers (Basel); 2019 Jun; 11(7):. PubMed ID: 31252648
[TBL] [Abstract][Full Text] [Related]
31. The potential role of immunotherapy to treat colorectal cancer.
Amin M; Lockhart AC
Expert Opin Investig Drugs; 2015 Mar; 24(3):329-44. PubMed ID: 25519074
[TBL] [Abstract][Full Text] [Related]
32. Antibody-Based Targeting of Cell Surface GRP94 Specifically Inhibits Cetuximab-Resistant Colorectal Cancer Growth.
Jeoung MH; Kim TK; Kim JW; Cho YB; Na HJ; Yoo BC; Shim H; Song DK; Heo K; Lee S
Biomolecules; 2019 Nov; 9(11):. PubMed ID: 31683810
[TBL] [Abstract][Full Text] [Related]
33. Bispecific antibodies in colorectal cancer therapy: recent insights and emerging concepts.
Ghalamfarsa F; Khatami SH; Vakili O; Taheri-Anganeh M; Tajbakhsh A; Savardashtaki A; Fazli Y; Uonaki LR; Shabaninejad Z; Movahedpour A; Ghalamfarsa G
Immunotherapy; 2021 Nov; 13(16):1355-1367. PubMed ID: 34641708
[TBL] [Abstract][Full Text] [Related]
34. Dietary phytochemicals in colorectal cancer prevention and treatment: A focus on the molecular mechanisms involved.
Afrin S; Giampieri F; Gasparrini M; Forbes-Hernández TY; Cianciosi D; Reboredo-Rodriguez P; Zhang J; Manna PP; Daglia M; Atanasov AG; Battino M
Biotechnol Adv; 2020; 38():107322. PubMed ID: 30476540
[TBL] [Abstract][Full Text] [Related]
35. Nanotechnology is an important strategy for combinational innovative chemo-immunotherapies against colorectal cancer.
Matos AI; Carreira B; Peres C; Moura LIF; Conniot J; Fourniols T; Scomparin A; Martínez-Barriocanal Á; Arango D; Conde JP; Préat V; Satchi-Fainaro R; Florindo HF
J Control Release; 2019 Aug; 307():108-138. PubMed ID: 31226355
[TBL] [Abstract][Full Text] [Related]
36. Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer.
Lee SY; Oh SC
Biomed Res Int; 2016; 2016():7590245. PubMed ID: 27127793
[TBL] [Abstract][Full Text] [Related]
37. Antibody-Loaded Nanoplatforms for Colorectal Cancer Diagnosis and Treatment: An Update.
Djermane R; Nieto C; Vega MA; Del Valle EMM
Pharmaceutics; 2023 May; 15(5):. PubMed ID: 37242756
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy with Immune Checkpoint Inhibitors for Advanced Colorectal Cancer: A Promising Individualized Treatment Strategy.
Yang Y; Meng WJ; Wang ZQ
Front Biosci (Landmark Ed); 2023 Apr; 28(4):69. PubMed ID: 37114536
[TBL] [Abstract][Full Text] [Related]
39. Current and advancing treatments for metastatic colorectal cancer.
Sanz-Garcia E; Grasselli J; Argiles G; Elez ME; Tabernero J
Expert Opin Biol Ther; 2016; 16(1):93-110. PubMed ID: 26549053
[TBL] [Abstract][Full Text] [Related]
40. Drug Repositioning for P-Glycoprotein Mediated Co-Expression Networks in Colorectal Cancer.
Beklen H; Gulfidan G; Arga KY; Mardinoglu A; Turanli B
Front Oncol; 2020; 10():1273. PubMed ID: 32903699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
